![]()
The U.S. Department of Health and Human Services (HHS) announced that it will stop developing new mRNA vaccines because, according to HHS Secretary Robert F. Kennedy, Jr, ” mRNA vaccines don’t perform well against viruses that infect the upper respiratory tract” and “paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine.”
This doesn’t mean mRNA vaccines are coming off the market. The government says several late-stage candidates will be allowed to “run their course to preserve prior taxpayer investment.” What’s being canceled are 22 new vaccine development projects—all government-funded.
Meanwhile, several mRNA-based cancer vaccines are in late-stage clinical trials, including personalized therapies for melanoma, pancreatic cancer, lung cancer, and more.
Private vaccine makers are free to continue developing new mRNA vaccines—but without government funding.
mRNA technology itself is not new. It’s based on a standard lab technique called “transfection,” which involves inserting RNA or DNA into eukaryotic cells. It has long been used in animal studies—especially in mice—and was tested in a limited number of human clinical trials before COVID. But it wasn’t until the COVID vaccine rollout that this technology was deployed at scale, turning us all into lab rats.
But again, mRNA isn’t going away. It’s just going private.
So the question remains:
Are we witnessing a quiet retreat from the mRNA revolution—or the beginning of a new phase, with fewer guardrails and even less public accountability?